Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


DexCom’s AI Powered Stelo Pushes Deeper Into Consumer Metabolic Health

2026-02-06
DexCom (NasdaqGS:DXCM) is upgrading its Stelo glucose monitoring platform with AI driven features that expand its nutrition database and deliver more personalized health insights. The new tools focus on meal tracking, individualized recommendations, and behavioral coaching to support users managing metabolic health. Stelo is being positioned as a consumer focused digital health offering alongside DexCom’s existing continuous glucose monitoring products. DexCom, trading at $69.89, sits at...

Wearables’ future in healthcare likely to hinge on actionable insights

2026-02-06
Wearables in healthcare must advance to a stage where they provide actionable insights in addition to datapoints.

1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds

2026-02-06
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features

2026-02-05
Dexcom plans a nationwide AI upgrade to Stelo, adding a million-plus food database and smarter insights to improve glucose understanding and wellness goals.

DexCom (DXCM) Reports Next Week: Wall Street Expects Earnings Growth

2026-02-05
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care

2026-02-05
ACTON, Mass., February 05, 2026--Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care

Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

2026-02-04
SAN DIEGO, February 04, 2026--Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose health and take steps in achieving their long-term health goals. The newest features will launch nationwide in the coming weeks.

DexCom’s Q4 Beat And 2026 Targets Tested By Rising CGM Competition

2026-02-01
DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this update with a positive outlook for 2026, outlining targets that support its longer term growth plans. These announcements come as competition in glucose monitoring intensifies and recent analyst views on NasdaqGS:DXCM have turned more mixed. DexCom, traded as NasdaqGS:DXCM, last closed at $73.04. The stock is up 9.8% over the past month and 9.8% year to date, but it...

What DexCom (DXCM)'s Strong Q4 Beat and 2026 Margin Guidance Means For Shareholders

2026-02-01
DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance for higher 2026 revenue and improved adjusted margins. This stronger operational outlook has prompted many analysts to reiterate positive ratings even as some highlight rising competition in DexCom’s core insulin-intensive segments. Next, we’ll examine how DexCom’s upbeat 2026 guidance for...

Q4 Preliminary Figures and 2026 Guidance Make DexCom (DXCM) Look Attractive

2026-01-30
DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment according to consensus. Out of 22 analysts who covered the stock, 18 assigned Buy ratings and 3 gave Hold calls. With just 1 […]